{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-078585","form_type":"8-K/A","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2024-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.023040+00:00","generated_at":"2026-05-31T22:39:46.188218+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"ArriVent appoints Kristine Peterson to Board; she joins Compensation Committee","bullets":["Kristine Peterson appointed as Class III director effective April 20, 2024, until 2027 annual meeting.","Appointed to Compensation Committee on July 3, 2024.","Received option grant with $352,500 fair value, vesting over three years; annual cash retainer of $45,000 prorated.","Peterson brings >30 years biopharma experience; former CEO of Valeritas, exec roles at J&J and BMS.","Currently on boards of Immunocore and Enanta; deemed independent under Nasdaq rules."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-078585","json":"https://secwatch.observer/filing/0001104659-24-078585.json","markdown":"https://secwatch.observer/filing/0001104659-24-078585.md","text":"https://secwatch.observer/filing/0001104659-24-078585.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000110465924078585/0001104659-24-078585-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000110465924078585/tm2419108-1_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:39:46.188218+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a10c39945c","claim":"Kristine Peterson was appointed as Director at ArriVent BioPharma, Inc..","evidence_excerpt":"On April 20, 2024, the Board of Directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) appointed Kristine Peterson to the Board, effective immediately (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1868279/000110465924078585/0001104659-24-078585-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}